Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2018

News Human

Five medicines recommended for approval, including two orphans

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended five medicines for approval, including two orphan medicines1, at its February 2018 meeting.

The CHMP recommended granting a marketing authorisation for Amglidia (glibenclamide), for the treatment of neonatal diabetes mellitus in newborns, infants and children. Because neonatal diabetes is a very rare disease, Amglidia was granted an orphan designation. For more information, please see the press release in the grid below.

The cancer medicine Mylotarg (gemtuzumab ozogamicin) received a positive opinion for the treatment of acute myeloid leukaemia in patients aged 15 years and above, giving young patients a new treatment option. Mylotarg has an orphan designation.

The Committee recommended granting a marketing authorisation for Alpivab (peramivir), for the treatment of uncomplicated influenza.

The CHMP granted a positive opinion for two informed consent applications for the maintenance treatment of adult patients with moderate to severe chronic obstructive pulmonary disease: Riarify2 (beclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium) and Trydonis (beclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium).

An informed consent application makes use of data from the dossier of a previously authorised medicine, with the marketing authorisation holder of that medicine giving consent for the use of their data in the application.

Negative opinion on two medicines

The CHMP adopted a negative opinion for Nerlynx (neratinib). Nerlynx was expected to be used to treat breast cancer.

The CHMP also adopted a negative opinion for an extension of therapeutic indication for Sutent (sunitinib).

For more information on these negative opinions, please see the questions-and-answers documents in the grid below.

Six recommendations on extensions of therapeutic indication

The Committee also recommended extensions of indications for Bosulif, Feraccru, Isentress, Kineret, Lynparza and Xgeva.

A press release on the extension of indication for Kineret for the treatment of Still's disease in children and adults is available in the grid below.

Withdrawal of application

An application to extend the use of Zydelig (idelalisib) for the treatment of chronic lymphocytic leukaemia has been withdrawn. A questions-and-answers document on this withdrawal is available below.

Agenda and minutes

The agenda of the February 2018 meeting is published on EMA's website. Minutes of the January 2018 CHMP meeting will be published in the coming weeks.

CHMP statistics

Key figures from the February 2018 CHMP meeting are represented in the graphic below.

More information on all other outcomes of the CHMP February 2018 meeting is available in the grid below.


1As always at time of approval, these orphan designations will now be reviewed by EMA's Committee for Orphan Medicinal Products (COMP) to determine whether the information available to date allows maintaining the medicines' orphan status and granting the medicines ten years of market exclusivity.

2Previously known as CHF 5993 Chiesi Farmaceutici S.p.A.

 

CHMP_highlights_February_2018.png

CHMP statistics: February 2018

 

Positive recommendations on new medicines

Name of medicine Alpivab
International non-proprietary name (INN) peramivir
Marketing-authorisation applicant Biocryst UK Limited
Therapeutic indication Treatment of uncomplicated influenza
More information CHMP summary of positive opinion for Alpivab

 

Name of medicine Amglidia
INN glibenclamide
Marketing-authorisation applicant Ammtek
Therapeutic indication Treatment of neonatal diabetes
More information

CHMP summary of positive opinion for Amglidia

Press release: First medicine to treat neonatal diabetes

 

Name of medicine Mylotarg
INN gemtuzumab ozogamicin
Marketing-authorisation applicant Pfizer Limited
Therapeutic indication Treatment of acute myeloid leukaemia
More information CHMP summary of positive opinion for Mylotarg

 

Positive recommendations on new informed-consent applications

Name of medicine Riarify (Previously known as CHF 5993 Chiesi Farmaceutici S.p.A.)
INN beclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium
Marketing-authorisation applicant Chiesi Farmaceutici S.p.A.
Therapeutic indication Maintenance treatment of adult patients with moderate to severe chronic obstructive pulmonary disease
More information CHMP summary of positive opinion for Riarify (Updated on 27/02/2018)

 

Name of medicine Trydonis
INN beclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium
Marketing-authorisation applicant Chiesi Farmaceutici S.p.A.
Therapeutic indication Maintenance treatment of adult patients with moderate to severe chronic obstructive pulmonary disease
More information CHMP summary of positive opinion for Trydonis

 

Negative recommendation on new medicine

Name of medicine Nerlynx
INN neratinib
Marketing-authorisation applicant Puma Biotechnology Ltd
Therapeutic indication Treatment of breast cancer
More information Questions and answers on the positive opinion on the marketing authorisation for Nerlynx (neratinib)

 

Positive recommendations on extensions of indications

Name of medicine Bosulif
INN bosutinib
Marketing-authorisation holder Pfizer Limited
More information CHMP post-authorisation summary of positive opinion for Bosulif

 

Name of medicine Feraccru
INN ferric maltol
Marketing-authorisation holder Shield TX (UK) Ltd
More information CHMP post-authorisation summary of positive opinion for Feraccru

 

Name of medicine Isentress
INN raltegravir
Marketing-authorisation holder Merck Sharp & Dohme Limited
More information CHMP post-authorisation summary of positive opinion for Isentress

 

Name of medicine Kineret
INN anakinra
Marketing-authorisation holder Swedish Orphan Biovitrum AB (publ)
More information

CHMP post-authorisation summary of positive opinion for Kineret

Press release: New treatment option for rare inflammatory disease

 

Name of medicine Lynparza
INN olaparib
Marketing-authorisation holder AstraZeneca AB
More information

 

Name of medicine Xgeva
INN denosumab
Marketing-authorisation holder Amgen Europe B.V.
More information CHMP post-authorisation summary of positive opinion for Xgeva (II-55)

 

Negative recommendation on extension of indication

Name of medicine Sutent
INN sunitinib
Marketing-authorisation holder Pfizer Limited
More information Questions and answers on refusal of a change to the marketing authorisation for Sutent (sunitinib)

 

Withdrawal of application for extension of indication

Name of medicine Zydelig
INN idelalisib
Marketing-authorisation applicant Gilead Sciences International Ltd.
More information Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Zydelig (idelalisib)

 

Other updates

 

Share this page